Skip to content

Congenital Adrenal Hyperplasia (CAH)

Peer reviewed Updated
Cite this article
AMA
MD A.. Congenital Adrenal Hyperplasia (CAH). My Endo Consult. Published January 11, 2025. Accessed October 4, 2026. https://myendoconsult.com/learn/topics/congenital-adrenal-hyperplasia-cah/
APA
MD A. (2025). Congenital Adrenal Hyperplasia (CAH). My Endo Consult. https://myendoconsult.com/learn/topics/congenital-adrenal-hyperplasia-cah/
Vancouver
MD A.. Congenital Adrenal Hyperplasia (CAH) [Internet]. My Endo Consult; January 11, 2025 [cited October 4, 2026]. Available from: https://myendoconsult.com/learn/topics/congenital-adrenal-hyperplasia-cah/
BibTeX
@online{myendoconsult4422394,
  author = {Akuffo Quarde, MD},
  title  = {Congenital Adrenal Hyperplasia (CAH)},
  organization = {My Endo Consult},
  year   = {2025},
  url    = {https://myendoconsult.com/learn/topics/congenital-adrenal-hyperplasia-cah/},
  urldate = {October 4, 2026}
}

CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)

General Overview

  • Definition: CAH comprises a group of autosomal recessive disorders characterized by enzyme deficiencies in the cortisol synthetic pathway.
  • Pathophysiology:
    • Decreased Cortisol → Lack of negative feedback → ↑ACTH → Adrenal hyperplasia & accumulation of precursor steroids.
    • Depending on the specific enzyme block, there may be loss or excess of mineralocorticoids or androgens.
  • Classic vs. Nonclassic:
    • Classic: Severe enzyme deficiencies, typically presenting in infancy.
    • Nonclassic (late-onset): Milder enzyme defects, presenting later in childhood or adulthood.
Adrenal Steroidogenesis

CONGENITAL LIPOID HYPERPLASIA

(StAR or P450scc Mutation)

  1. Enzyme/Protein Defect
    • Mutations in Steroidogenic Acute Regulatory Protein (StAR) or P450 side-chain cleavage enzyme (P450scc).
  2. Hormone Deficiency
    • Deficiency in all adrenal and gonadal steroid hormones (glucocorticoids, mineralocorticoids, sex steroids).
  3. Pathology
    • Marked accumulation of cholesterol esters in the adrenal cortex (due to ACTH drive with no steroid synthesis).
  4. Clinical Presentation
  5. Laboratory Findings
    • Low serum cortisol & aldosterone, high ACTH, high plasma renin activity.
  6. Outcome and Treatment
    • Lethal if untreated.
    • Glucocorticoid + mineralocorticoid replacement therapy is essential.

3β-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY

(3β-HSD2 Mutation)

  1. Function
    • 3β-HSD converts pregnenolone → progesterone, also DHEA → androstenedione.
    • Type 2 isoenzyme (3β-HSD2) is present in adrenal cortex and gonads.
  2. Hormone Deficiency
    • Cortisol, aldosterone, gonadal steroid production severely reduced.
    • ↑Δ⁵-steroids (pregnenolone, 17-hydroxypregnenolone, DHEA, DHEA-S).
  3. Clinical Presentation
    • Severe deficiency: Neonatal salt-wasting adrenal crisis (cortisol & aldosterone deficiency).
    • Mild virilization in 46,XX infants (excess DHEA).
    • 46,XY phenotype can vary from normal male to ambiguous or female genitalia.
  4. Laboratory Findings
    • Low cortisol, low aldosterone, ↑DHEA, DHEA-S, but androstenedione not elevated (needs 3β-HSD).
    • ↑Renin activity (salt-wasting).
  5. Treatment
    • Glucocorticoid & mineralocorticoid replacement + sex steroid replacement at puberty if needed.

17α-HYDROXYLASE DEFICIENCY

(CYP17A1 Mutation)

  1. Enzyme/Pathway
    • 17α-hydroxylase (P450c17) required for 17-hydroxylation → glucocorticoids & sex steroids.
    • Also has 17,20-lyase activity → androgens.
  2. Hormonal Effects
    • ↑Mineralocorticoid precursors (11-deoxycorticosterone, corticosterone) → hypertension, hypokalemia.
    • ↓Androgens & estrogens → lack of pubertal sexual development.
  3. Clinical Presentation
    • Often found at puberty due to sexual infantilism.
    • 46,XX: Primary amenorrhea, no secondary sexual characteristics, HTN, hypokalemia.
    • 46,XY: Phenotypic female (externally), but no internal female structures, intraabdominal testes, no puberty, HTN, hypokalemia.
  4. Laboratory Findings
    • Hypokalemia, low plasma renin, low aldosterone (corticosterone suffices for MR effect).
    • High DOC, high corticosterone, low 17-hydroxyprogesterone, low cortisol, low sex steroids.
  5. Treatment

21-HYDROXYLASE DEFICIENCY

(CYP21A2 Mutation)

  1. Incidence
    • >90% of CAH cases, autosomal recessive.
  2. Hormone Effects
    • Defect in conversion:
      • Progesterone → 11-deoxycorticosterone (mineralocorticoid branch).
      • 17-hydroxyprogesterone → 11-deoxycortisol (glucocorticoid branch).
    • Excess: 17-hydroxyprogesterone, progesterone, adrenal androgens.
  3. Clinical Presentation
    • Classic Salt-Wasting: Severe deficiency → life-threatening neonatal salt-losing crisis, ambiguous genitalia in 46,XX.
    • Classic Simple Virilizing: Some mineralocorticoid function preserved; virilization but no salt-wasting.
    • Nonclassic (late-onset): Milder, partial enzyme defect.
  4. Laboratory Findings
    • ↑17-hydroxyprogesterone (often > 6x normal).
    • Low cortisol, low aldosterone in salt-wasters, ↑ACTH, ↑renin.
    • ↑Androstenedione, ↑testosterone, decreased 11-deoxycortisol.
  5. Diagnosis
    • Newborn screening (17-hydroxyprogesterone test).
  6. Treatment
    • Glucocorticoid & mineralocorticoid replacement.
    • Surgical correction of ambiguous genitalia if needed.

11β-HYDROXYLASE DEFICIENCY

(CYP11B1 Mutation)

  1. Enzyme/Pathway
    • Converts 11-deoxycortisol → cortisol in fasciculata, and 11-deoxycorticosterone (DOC) → corticosterone in glomerulosa.
  2. Hormonal Effects
    • ↑11-deoxycortisol, ↑DOC, ↑adrenal androgens.
    • DOC has mineralocorticoid activity → hypertension, hypokalemia, suppressed renin, low aldosterone.
  3. Clinical Presentation
    • Severe deficiency: Neonatal virilization (46,XX ambiguous genitalia), salt retention (HTN).
    • Partial deficiency: Hypertension, possible precocious puberty, or young adult onset of HTN, hirsutism, oligomenorrhea.
  4. Laboratory Findings
    • ↑11-deoxycortisol, ↑DOC, ↑DHEA, DHEA-S, androstenedione, testosterone.
    • Hypokalemia, low renin, low aldosterone, high ACTH.
  5. Treatment
    • Glucocorticoid replacement ± mineralocorticoid considerations (though often suppressed renin–aldosterone axis already).

APPARENT MINERALOCORTICOID EXCESS

(11β-HSD2 Deficiency)

  1. Enzyme
  2. Pathophysiology
    • Decreased 11β-HSD2 → cortisol not inactivated → binds mineralocorticoid receptor → HTN, hypokalemia, metabolic alkalosis, low renin, low aldosterone, normal cortisol levels.
    • May be hereditary or from licorice (glycyrrhizic acid) ingestion.
  3. Diagnosis
    • Abnormal 24-hour urinary ratio of cortisol : cortisone (>10:1).
    • Also seen in ectopic ACTH with massive cortisol production overwhelming 11β-HSD2.
  4. Clinical
    • Severe HTN, hypokalemia, suppressed RAAS.
    • Treated with mineralocorticoid receptor antagonists (e.g., spironolactone) or correct the underlying cause.

MAJOR BLOCKS IN ABNORMAL STEROIDOGENESIS (SUMMARY)

  1. Congenital Lipoid Hyperplasia (StAR or P450scc)
  2. 3β-HSD Deficiency
  3. 17α-Hydroxylase Deficiency (CYP17A1)
  4. 21-Hydroxylase Deficiency (CYP21A2)
  5. 11β-Hydroxylase Deficiency (CYP11B1)

Additional Points

  • Aldosterone Synthase (P450c11AS) in zona glomerulosa converts corticosterone → aldosterone (via 18-hydroxylation).
  • Zona Glomerulosa lacks 17α-hydroxylase, cannot synthesize cortisol.
  • Zona Reticularis: high cytochrome b5 → strong 17,20-lyase activity → DHEA production.
  • Interconversion: 11β-HSD1 (liver) → cortisone → cortisol; 11β-HSD2 (kidney) → cortisol → cortisone.